Candel Therapeutics Inc (NASDAQ: CADL) on Friday, plunged -5.53% from the previous trading day, before settling in for the closing price of $6.15. Within the past 52 weeks, CADL’s price has moved between $3.79 and $14.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -43.86% annually for the last half of the decade. The company achieved an average annual earnings per share of 70.11%. With a float of $36.70 million, this company’s outstanding shares have now reached $49.25 million.
In an organization with 38 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Candel Therapeutics Inc (CADL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Candel Therapeutics Inc is 31.18%, while institutional ownership is 36.00%. The most recent insider transaction that took place on Jun 30 ’25, was worth 3,936. In this transaction Chief Medical Officer of this company sold 781 shares at a rate of $5.04, taking the stock ownership to the 52,493 shares. Before that another transaction happened on Jun 30 ’25, when Company’s Officer proposed sale 3,593 for $4.90, making the entire transaction worth $17,606.
Candel Therapeutics Inc (CADL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 70.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 56.83% during the next five years compared to -43.86% drop over the previous five years of trading.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Candel Therapeutics Inc (CADL) is currently performing well based on its current performance indicators. A quick ratio of 4.64 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.68 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
Let’s dig in a bit further. During the last 5-days, its volume was 1.25 million. That was better than the volume of 1.1 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 79.34%.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 16.54%, which indicates a significant decrease from 68.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.34 in the past 14 days, which was lower than the 0.54 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.29, while its 200-day Moving Average is $6.36. However, in the short run, Candel Therapeutics Inc’s stock first resistance to watch stands at $6.03. Second resistance stands at $6.24. The third major resistance level sits at $6.36. If the price goes on to break the first support level at $5.69, it is likely to go to the next support level at $5.56. Assuming the price breaks the second support level, the third support level stands at $5.35.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
Market capitalization of the company is 309.81 million based on 50,103K outstanding shares. Right now, sales total 0 K and income totals -55,180 K. The company made 0 K in profit during its latest quarter, and 7,380 K in sales during its previous quarter.
